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Abstract:  35 
Context: The endocrine function of human fetal adrenals (HFA) is activated already during first trimester, but 36 
changes in adrenal steroidogenesis during fetal life are not well characterized.  37 
Objective: This study aimed to investigate HFA steroidogenesis by analyzing adrenal glands from 1st and 2nd 38 
trimester. 39 
Design and Setting: Male and female HFA samples from gestational week (GW) 8-19 were examined, 40 
including a total of 101 samples from 83 fetuses.  41 
Main Outcome Measure(s): Expression level of steroidogenic genes and protein expression/localization were 42 
determined by quantitative PCR and immunohistochemistry, respectively, and intra-adrenal steroid levels were 43 
quantified by LC-MS/MS.  44 
Results: Transcriptional levels of StAR, CYP11A1, CYP17A1, CYP21A2, CYP11B1/2 and SULT2A1 was 45 
significantly higher in 2nd trimester compared with 1st trimester (P<0.05), while expression levels of 3β-HSD2 46 
and ARK1C3 were unaltered between GW 8-19. All investigated steroidogenic proteins were expressed in a 47 
distinct pattern throughout GW 8-19 with most enzymes expressed primarily in the fetal zone, except 3β-48 
HSD1/2 which was mainly expressed in the definitive zone. The abundant steroidogenic enzyme expression 49 
was reflected in overall high intra-adrenal tissue concentrations of mineralocorticoids, glucocorticoids, and 50 
androgens; cortisol was the most abundant (1,071-2,723 ng/g tissue, in average) and testosterone levels the 51 
lowest (2-14 ng/g tissue, in average).  52 
Conclusions: The expression profiles of HFA steroidogenic enzymes are distinct from 1st to 2nd trimester, with 53 
no major differences between male and female samples. The intra-adrenal steroid hormone concentrations 54 
confirms that cortisol is produced throughout 1st and 2nd trimester, suggesting continued regulation of the HPA 55 
axis during this entire period.  56 
 57 
Introduction 58 
The morphology of the human fetal adrenal (HFA) gland differs from the adult organ. Thus, the morphology of 59 




adreno-genital primordial cells into a distinct morphology consisting of two separate zones; a thin outer 61 
definitive zone (DZ) and an inner fetal zone (FZ) that accounts for 80-90% of the adrenal tissue (1). During 2nd 62 
trimester an additional transitional zone (TZ) develops at the interface between the DZ and FZ after which the 63 
morphology of the HFA gland is unchanged until birth (1). 64 
 65 
Activation of the hypothalamus-pituitary-adrenal (HPA) hormone axis is essential for adrenal steroidogenic 66 
enzyme expression (2). Thus, activation of the adrenal melanocortin receptor 2 (MC2R) through binding of 67 
pituitary-secreted adrenocorticotropic hormone (ACTH) is necessary for the endocrine capacity of the HFA 68 
gland (1,3,4). The FZ (and later TZ) is described as the most steroidogenic active zone expressing 69 
Steroidogenic acute regulatory protein (StAR), Cytochrome P450 11A1 (CYP11A1), Cytochrome P450 17A1 70 
(CYP17A1), Cytochrome P450 21A2 (CYP21A2), Cytochrome P450 11B (CYP11B1/ CYP11B2) and 71 
Sulfotransferase Family 2A Member 1 (SULT2A1) from around GW 7 (4,5,6). Throughout gestation CYP17A1 72 
and SULT2A1 are exclusively localized to the FZ and TZ (1,7-9) while CYP11A1, CYP21A2 and StAR are also 73 
expressed in the DZ from around GW 23 (7,8,10,11).  74 
 75 
3β-hydroxysteroid dehydrogenase type 2 (3β-HSD2) mediates the adrenal de novo synthesis of Δ4 steroid 76 
hormones. Since the adrenal expression of 3β-HSD1 is very low compared to 3β-HSD2 (4,12) the detection 77 
of 3β-HSD1/2 in this study is thought mainly to represent expression of 3β-HSD2. In contrast to the other HFA 78 
steroidogenic enzymes, 3β-HSD2 is mainly expressed in DZ cells from GW 7-10 (3,4,7,8,11). However, a 79 
recent study showed a constant 3β-HSD2 expression throughout 2nd trimester (13). This finding suggests that 80 
the 3β-HSD2 enzyme in addition to its role in the regulation of fetal adrenal cortisol-mediated negative 81 
feedback on the HPA axis to minimize adrenal androgen synthesis during the critical time window of sex 82 
differentiation (4,14-16) also may act as a negative regulator throughout 2nd trimester.    83 
 84 
HFA steroidogenesis is tightly regulated throughout the 1st and 2nd trimester which is crucial as the adrenal 85 
steroid hormones affect the overall endocrine intrauterine environment from early fetal development. Elevated 86 
levels of HFA androgens can be a consequence of dysregulated adrenal steroid pathways, in which 87 




congenital adrenal hyperplasia (17). However, HFA steroidogenesis is not well characterized during fetal 89 
development as previous studies investigating the steroidogenic function have focused on either 1st or 2nd/3rd 90 
trimester only, characterizing selected adrenal steroidogenic enzymes. This study therefore aimed to collect 91 
detailed expression-data of all the classical steroidogenic enzymes and determine the intra-adrenal steroid 92 
levels from 1st and 2nd trimester HFA’s in one inclusive study.  Thus, this study is the first to examine both 93 
human fetal-adrenal-tissue steroid levels, gene and protein expression of steroidogenic enzymes throughout 94 
1st and 2nd trimester fetal development.  95 
Material and Methods 96 
Collection of human fetal adrenals and ethical approvals  97 
Human fetal adrenal tissue from 1st trimester (8-12 GW) and 2nd trimester (14-19 GW) were isolated from 98 
material available following elective surgical termination of pregnancy at Copenhagen University Hospital 99 
(Rigshospitalet) and Hvidovre Hospital (Denmark) as well as the Royal Infirmary of Edinburgh (UK) and the 100 
Human Developmental Biology Resource (UK). A total of 101 HFA samples were used in this study collected 101 
from 83 individual fetuses as two adrenals from the same fetus was occasionally used in different analyses. 102 
The study is approved by the Danish regional ethics committee (H-1-2012-007) and the UK Lothian Research 103 
Ethics committee (LREC08/S1101/1). Woman gave their informed written and oral consent. None of the 104 
terminations were for reasons of fetal abnormality, and all fetuses appeared morphologically normal. Fetal age 105 
was determined by scanning crown-rump length and confirmed by evaluation of foot length (18). Hence, fetal 106 
age will be about 2 weeks greater than studies reporting days/weeks post conception. After dissection, adrenal 107 
tissue samples were either snap frozen at -80 °C or fixed immediately in 4% buffered formalin. Fetal sex 108 
determination was based on PCR using specific primers targeting SRY. DNA for sex determination was 109 
extracted from fetal limb tissue and isolated with NucleoSpin Genomic DNA as described by the manufacture 110 
(Macherey-Nagel, Düren, Germany). PCR cycle conditions: one cycle of 3 min at 95°C; 25 cycles of 30 sec at 111 




Gene expression 113 
Total RNA was extracted from one frozen HFA glands in samples from GW 8-12 (11 male and 11 female, 114 
collected from 22 fetuses), while half of a frozen HFA gland was used in samples from GW 14-19 (9 male and 115 
8 female, collected from 17 fetuses and isolated using the NucleoSpin RNA II purification kit, according to the 116 
manufactures instructions (Macherey-Nagel, Düren, Germany). cDNA was synthesized using a dT20 primer 117 
and random hexamers. Real time polymerase chain reaction (RT-PCR) was performed using specific primers 118 
targeting preselected mRNAs. All primers were designed to span intron-exon boundaries with optimal 119 
annealing temperatures ~62 °C, comparable primer length and CG contents (Table 1). All amplicons were 120 
initially verified by sequencing (Eurofins MWG GmbH, Germany) while primer amplification efficiency and 121 
detectable dynamic range of all primer-sets was validated prior to the analysis of the HFA samples. RT-PCR 122 
cycle conditions: one cycle of 3 min at 95°C; 40 cycles of 30 sec at 95°C, 1 min at 62°C, 1 min at 72°C, and 123 
one cycle of 5 min at 72°C. Quantitative RT-PCR analysis was performed in triplicates using Brilliant II SYBER 124 
Green qPCR Master mix (Agilent technologies). Changes in gene expression were quantified using the 2-ΔΔCt 125 
method (19). The expression levels were normalized to the reference gene, RSP20, and calculated as a ratio 126 
with male or female GW 8-9 set to 1 in respective samples. 127 
Immunohistochemistry  128 
Adrenal tissue from GW 8-12 (13 male and 13 female, collected from 26 fetuses) and GW 14-19 (10 male and 129 
6 female, collected from 16 fetuses) were used for immunohistochemistry. Formalin fixed adrenal tissue were 130 
dehydrated, paraffin embedded and sectioned (4 µm) using standard procedures. Primary antibodies, dilutions 131 
and retrieval buffers are listed in Table 2. Immunohistochemistry (IHC) staining was initially conducted 132 
according to a standard protocol as described previously (20). Subsequently, the protocol was modified to 133 
include antigen retrieval by pressure cooker as previous described (21). In brief, tissue sections were 134 
subjected to heat-induced antigen retrieval buffer in a pressure cooker and endogenous peroxidase was 135 
blocked with 3% (v/v) H2O2 in MeOH for 30 min. Between each step sections were washed in Tris-buffered 136 
Saline (TBS). Sections were incubated in 5% bovine serum albumin (BSA w/v) in Horse serum (20% v/v 137 




Sections were subsequently incubated overnight with primary antibody diluted in serum at 4°C in a humidified 139 
chamber followed by 1h at room temperature. Sections were then incubated for 30 min with the appropriate 140 
ImmPRESS HRP (peroxidase) secondary antibody diluted in normal serum. Visualization was performed using 141 
ImmPACT AEC peroxidase substrate (Vector Laboratories, Burlingame, CA, USA). Included negative controls 142 
replaced the primary antibody with dilution buffer only, none of which showed any staining. All sections were 143 
counterstained with Meyer’s hematoxylin before mounting with Aquatex (Merck, Damstad, Germany). 144 
Quantification of stained cells  145 
Two independent investigators evaluated all stainings. Sections were first investigated manually on a Nikon 146 
Microphot-FXA microscope, subsequently slides were scanned on a Nano-Zoomer 2.0 HT (Hamamatsu 147 
Photonics, Herrsching am Ammersee, Germany) and analyzed using the software NDPview version 1.2.36 148 
(Hamamatsu Photonics). The intensity of immunoreactivity was classified according to a pre-defined scoring 149 
system: ++, strong staining in all cells of a given type in the sample; ++/+, strong staining prevalent, but some 150 
weakly stained cells also visible; ++/-, strong staining present, but negative cells also present; +/++, majority 151 
of cells weakly stained, but some strong staining present; +/++/-, heterogeneous pattern with a mixture of 152 
strongly positive, weakly stained, and negative cells; +, (1) weak staining overall or (2) strong staining in a 153 
small number of cells; +/-, weak staining in limited areas; -/+, weak staining in single cells. 154 
Quantification of steroid hormones 155 
Tissue samples from intact HFA glands GW 8-12 (10 male and 10 female, collected from 20 fetuses) and 156 
halved HFA glands GW 14-19 (9 male and 8 female, collected from 17 fetuses) were included for the intra-157 
adrenal steroid analysis by LC-MS/MS measurements. Tissue samples were weighed (1.7 mg - 43 mg wet 158 
weight) and ground in 1 mL 80% (v/v) MeOH. The homogenate was transferred to glass tubes evaporated to 159 
almost dryness under a N2 stream. Internal standard stock solution (5-500 ng/mL in 100 µL) was added to 160 
each sample pellet as previously described (22) and subsequently 375 µL 1M ammonium acetate buffer (pH 161 
5.5) was added. Next, 2 mL Heptan: Ethylacetat 3:2 (v/v) was added and samples were transferred to 162 
eppendorf tubes. Samples were then shaken for 15 min followed by 10 min of centrifugation at 2000 x g (4°C). 163 




aqueous phase followed by decantation of the organic phase to a new glass tube. The organic phase was 165 
evaporated to dryness under a stream of N2 and finally, the steroids were resolved in an appropriate amount 166 
of 50% (v/v) MeOH (tissue GW 8-12: 100 µL, tissue GW 14-19; 200 µL) for LC-MS/MS analysis as previously 167 
described (22). All samples were measured in one single batch which includes standards for calibration curves, 168 
unknown samples, two blanks and for method control; three un-spiked human serum pool samples and three 169 
serum pool samples spiked with low and high levels, respectively.  170 
Statistical analysis 171 
qPCR and LC-MS/MS data were statistically analyzed for age and sex specific differences. Age differences 172 
were tested by the nonparametric Mann-Whitney test in which HFA age groups GW: 10-12, GW: 14-16 and 173 
GW:17-19 were compared with male GW 8-9. Sex differences were also tested by nonparametric Mann-174 
Whitney test within each age group. P<0.05 was considered statistically significant.  175 
Results 176 
Gene expression patterns of adrenal steroidogenic enzymes  177 
The selected steroidogenic enzymes were expressed in all investigated HFA glands at the transcriptional level. 178 
Gene expression patterns were investigated separately in male and female samples, which were divided into 179 
four age groups: GW 8-9, GW 10-12, GW 14-16, and GW 17-19. Expression levels were calculated as a ratio 180 
of levels relative to male GW 8-9 (reference value set to 1). No sex differences were observed in the 181 
transcription levels of the examined steroidogenic enzymes nor in the transcription levels of the ACTH 182 
receptor, MC2R, throughout the investigated developmental period (Figure 1). During 2nd trimester, the 183 
expression level of StAR, CYP11A1, CYP17A1, SULT2A1 and MC2R increased approximately 10-fold, while 184 
the expression level of CYP21A2 and CYP11B1/2 increased even further by >50-fold and >20 fold, 185 
respectively (Figure 1e-f). Only two of the investigated steroidogenic enzymes were constitutively expressed 186 
throughout 1st and 2nd trimester, namely: 3β-HSD2 and aldo-keto reductase family I member C3 (ARK1C3, 187 
also known as 17βHSD3) (Figure 1d,g). Additionally, the absolute gene expression levels of 3β-HSD2 and 188 




Distribution of steroidogenic enzymes in the human fetal adrenal cortex 190 
The morphology of fixed adrenal samples included in the study was thoroughly examined. All samples 191 
appeared morphologically normal containing distinct zones in accordance with the gestational age of the 192 
developing HFA gland (Figure 2). Sections were stained with hematoxylin and eosin as well as Meyer’s 193 
hematoxylin. The DZ consisted of small cells, while FZ cells were larger with a high content of cytoplasm 194 
(Figure 2c). As expected, the TZ was detected in 2nd trimester samples and consisted of a mixture of small 195 
distinct DZ cells and larger distinct FZ cells (Figure 2d) as previous described (1).    196 
 197 
The expression profiles of steroidogenic proteins were analyzed using IHC on fixed adrenal samples. No 198 
differences between male and female samples were observed regarding the level of expression and the cell-199 
type specific enzyme localization. Therefore, only male samples are shown for the age groups GW 8-9, GW 200 
10-12, GW 14-16, and GW 17-19 in Figure 3. Adrenal zone-specific protein expression, localization, and the 201 
level of expression were evaluated based on a predefined scale and are summarized in Table 3.  202 
 203 
Most of the investigated steroidogenic enzymes were abundantly expressed in the FZ throughout development 204 
of both 1st and 2nd trimester (Figure 3). More specifically, CYP11A1, CYP21A2 and SULT2A1 were abundantly 205 
expressed in the cytoplasm of 1st trimester FZ cells and weakly expressed in a limited number of DZ cells 206 
towards late 1st and throughout 2nd trimester. CYP17A1 showed a similar expression and localization pattern, 207 
although CYP17A1 was expressed specific in the FZ except for a few strongly-positive cells scattered within 208 
the DZ in both 1st and 2nd trimester samples. During 2nd trimester, protein expression of CYP17A1 increased 209 
around the TZ as it decreased in the cells of the inner FZ. In contrast, 3β-HSD1/2 was the only observed 210 
steroidogenic enzyme which was frequently expressed in a limited number of DZ cells and only very few FZ 211 
cells. During 2nd trimester 3β-HSD1/2 was still abundantly expressed though only in a sub-population of DZ 212 
and FZ cells compared with 1st trimester samples. Like the steroidogenic enzymes, the ACTH receptor MC2R 213 
was also detected throughout the investigated period of fetal development. More specifically, weak 214 
cytoplasmic MC2R expression was detected throughout 1st and 2nd trimester, but nuclear MC2R expression 215 




patterns observed in this study should be interpreted with caution due to the unexpected nuclear expression 217 
(23), which is most likely an artifact of the antibody.  218 
Human fetal adrenal Steroid tissue concentrations  219 
The endocrine activity of the HFA was further evaluated by determination of the intra-adrenal steroid 220 
concentrations. Thus, steroids were extracted from adrenal gland tissue followed by LC-MS/MS determination 221 
of mineralocorticoid, glucocorticoid and androgen levels. Samples were divided according to sex and age (as 222 
described previously). All investigated mineralocorticoids, glucocorticoids and androgen metabolites were 223 
detected in HFA tissue from GW 8-19.  224 
 225 
The measured concentrations of mineralocorticoid metabolites progesterone and corticosterone were in 226 
general equivalent with no significant difference in relation to neither gestational age nor sex. The only 227 
exception was a significant age-related increase in female corticosterone levels at GW 17-19 compared with 228 
male tissue concentrations at GW 8-9 (Figure 4a). The intra-adrenal levels of glucocorticoids 17OH-229 
progesterone was unaltered over the investigated developmental period with no differences between male 230 
and female adrenal tissue samples were detected. In contrast, both 11-deoxycortisol, cortisol and cortisone, 231 
a significant increase in intra-adrenal steroid concentrations was found at GW 17-19 compared with male GW 232 
8-9 (Figure 4b). For 11-deoxycortisol a significant increase in intra-adrenal steroid concentrations was further 233 
observed at GW 10-12 and GW 14-16, the latest only in male samples. The only observed sex-specific 234 
difference was found in the intra-adrenal cortisone concentrations which were significantly higher in female 235 
samples at GW 8-9 compared with age matched males (Figure 4b). Interestingly, cortisol levels were the 236 
highest of all measured intra-adrenal steroid hormones throughout the investigated developmental period. 237 
Hence, cortisol tissue concentrations were approximately 2-fold higher than those of 17OH-progesterone and 238 
11-deoxycortisol and approximately 10-fold higher than cortisone (Figure 4b).  239 
 240 
Similar to the trend for the majority of measured steroid hormones, the adrenal tissue concentration of 241 
androgens was relatively constant throughout GW 8-19, only in male GW 14-16 samples a significant increase 242 




adrenal conversion of androstenedione to testosterone appeared to be limited as tissue concentrations of 244 
androstenedione were approximately 80-fold higher than testosterone (Figure 4c).   245 
 246 
Discussion 247 
This study investigated the adrenal steroidogenic expression pattern during the 1st and 2nd trimester of human 248 
fetal development. HFA glands function as active endocrine organs from early fetal development, which was 249 
confirmed by this study demonstrating expression of all investigated steroidogenic enzymes both at the gene 250 
and protein level in all investigated samples from GW 8-19. The distinct morphological expression pattern of 251 
the investigated enzymes is in accordance with previous studies focusing on either 1st or 2nd trimester human 252 
adrenals (4,7,8,10,11,13,14). Thus, our data support the prominent hypothesis of the FZ, and later in 253 
development also the TZ, being the main site of de novo steroid synthesis in the HFA. Interestingly, the 254 
transcription of steroidogenic genes appeared to be regulated differently with unaltered expression of ARK1C3 255 
and 3β-HSD2 during the investigated period while the expression of the other steroidogenic enzymes (StAR, 256 
CYP11A1, CYP17A1, CYP21A2, CYP11B1/2, and SULT2A1) and the ACTH receptor MC2R were significantly 257 
increased in 2nd trimester. The observed increases in gene expression levels in 2nd trimester was not evident 258 
at the protein level; presumably due to the lack of sensitivity of immunohistochemistry to detect differences in 259 
expression level. However, the genes upregulated during 2nd trimester were also the steroidogenic enzymes 260 
that showed the most abundant immunostaining in the FZ while the low constitutively expressed 3β-HSD1/2 261 
was only detected in a small subpopulation of cells mainly located in the DZ. Furthermore, the up-regulation 262 
in gene expression for the majority of the investigated steroidogenic enzymes was not reflected in higher tissue 263 
concentrations of steroidogenic hormones which overall did not differ between 1st and 2nd trimester (Figure 264 
5b). It remains to be examined whether the 2nd trimester transcriptional upregulation of steroidogenic enzymes 265 
are reflected in steroid levels secreted by the HFA to the fetal circulation, which were not possible to determine 266 





The constitutive expression of 3β-HSD1/2 throughout 1st and 2nd trimester of human fetal development in male 269 
and female HFA samples is in contrast with the previous reported transient expression profile (3,4,7,8,11). 270 
Thus, our results demonstrate that 3β-HSD1/2 is highly expressed in a sub-population of DZ cells from GW 8-271 
19, which is in accordance with recent published data (13). Even though the percentage of 3β-HSD1/2 positive 272 
cells in DZ and FZ appeared to decrease during 2nd trimester, this study is the first to report a small number of 273 
3β-HSD1/2 positive FZ cells in 2nd trimester fetuses up to GW 19. In general, the small number of 3β-HSD1/2 274 
positive cells compared with the abundant expression of the majority of the adrenal steroidogenic enzymes is 275 
consistent with the reported low 3β-HSD2 transcripts levels in this study as well as previous reports 276 
(3,4,11,13). The immediate imbalance between the low 3β-HSD1/2 expression and high tissue concentrations 277 
of the 3β-HSD2 catalyzed Δ4 steroids: progesterone, 17OH-progesterone, and androstenedione, has 278 
previously been suggested to be the result of either circulating placental progesterone or the transfer of 279 
intermediates of the steroid pathways between the adrenal zones (13). Since it has been shown by double 280 
immunofluorescence staining in 2nd trimester HFAs, CYP11A1 and CYP21A2 only co-localize in a limited 281 
number of FZ cells (13) this could support the hypothesis of transport of steroidogenic intermediates between 282 
the adrenal zones. Moreover, the presence of high levels of intra adrenal androstenedione in 2nd trimester 283 
determined in this study favors 3β-HSD2 dependent de novo synthesis, as 17OH-progesterone is a poor 284 
substrate for human CYP17A1 (C17,20 lyase) (24) indicating that adrenal androstenedione is not likely 285 
generated from placental progesterone.   286 
 287 
The HFA’s produce androgens throughout 1st and 2nd trimester in both male and female samples. The 288 
detection of high HFA tissue concentrations of androstenedione and low levels of testosterone indicate that 289 
this step-in steroidogenesis is tightly regulated. The low intra-adrenal testosterone levels detected from GW 290 
8-19 are in accordance with previous studies that have examined both fetal adrenal tissue concentrations and 291 
secreted levels in organ culture (3,4,13). Furthermore, the low tissue concentrations of testosterone are also 292 
in accordance with the relatively low transcriptional expression level of ARK1C3 which mediates adrenal de 293 
novo testosterone synthesis. The expression level of ARK1C3 in 1st trimester samples detected in this study 294 
supports previous investigations (3,4) while ARK1C3 expression levels, to our knowledge, have not been 295 




levels at GW 14-16, compared with male GW 8-9, is inconsistent with the observed overall unaltered 297 
expression level of ARK1C3 suggesting that testosterone levels are not only regulated via gene transcription. 298 
The observed peak in male testosterone around GW 14-16 is not significantly different from the female GW 299 
14-16 age group and it is likely that the adrenal testosterone production is considerably lower than the 300 
contribution from fetal testis (25). Moreover, this study is the first to report androstenedione as the most 301 
abundant Δ4 adrenal androgen synthesized by the classical steroidogenic pathway throughout 1st and 2nd 302 
trimester in HFA, which is in contrast to previous observations of higher adrenal androgen production during 303 
the 1st trimester (13).  304 
 305 
The HFA produces cortisol throughout 1st and 2nd trimester indicating continued regulation of the HPA axis 306 
during this entire period. In line with this finding is the detection of cytoplasmic MC2R expression from GW 8, 307 
which is in accordance to previous studies (3,4). However, due to the unexpected nuclear expression pattern 308 
of MC2R observed in this study these results should be interpreted with caution as MC2R is known to be 309 
expressed in the cytoplasm (at the endoplasmic reticulum) until its translocated with MRAP to the plasma 310 
membrane to mediate ACTH signaling (23).The abundant HFA tissue concentrations of cortisol detected in 311 
this study further supports the recent hypothesis that cortisol-mediated negative feedback of the HPA axis is 312 
not restricted to the 1st trimester, but extends through the 2nd trimester (13) including GW 14-19. Detection of 313 
intra-adrenal cortisol in 2nd trimester is consistent with the observed expression of 3β-HSD1/2 and in 314 
accordance with a previous study detecting cortisol in HFA tissue from 2nd trimester (13) although the cortisol 315 
concentrations measured in the present study are approximately 10-fold higher than the concentrations 316 
previously reported.  During GW 8-14 cortisol mediated negative feedback on the HPA axis is thought to be 317 
crucial since this period is the window of development in which the external genitalia differentiates (15,16). 318 
Hence, dysregulated adrenal steroidogenesis resulting in imbalance with excess of adrenal androgens and 319 
reduced cortisol in this time window can thus cause virilization of female genitalia in fetuses with CAH (17). 320 
Since adrenal androgens can be converted to estrogens by the placental aromatase (CYP19A1) later in 321 
pregnancy, the adrenal secretion of androgens during 2nd trimester is thought to have less effect on genital 322 
differentiation (15,16). However, the observed abundant concentration of cortisol throughout 1st and 2nd 323 




virilization of CAH fetuses during 2nd trimester or may possibly influence other events during human fetal 325 
development.  326 
 327 
This study provides a detailed characterization of both male and female adrenal endocrine function during 1st 328 
and 2nd trimester of human fetal development. It is evident from the gene and protein expression pattern of 329 
steroidogenic enzymes as well as the steroid measurements in tissue that the HFA functions as a 330 
steroidogenic active organ from early development by producing high levels of mineralocorticoids, 331 
glucocorticoids and androgens. Even from GW 8 we report a distinct expression pattern for the investigated 332 
adrenal steroidogenic enzymes with a significant increase of gene expression in 2nd trimester samples for the 333 
majority of enzymes, with exception of the unaltered expression of 3β-HSD2 and ARK1C3. Based on the intra-334 
adrenal steroid hormone concentrations we found that the androstenedione is the most abundant Δ4 adrenal 335 
androgen synthesized via the classical steroidogenic pathway throughout 1st and 2nd trimester. Additionally, 336 
this study confirms that cortisol is produced throughout 1st and 2nd trimester, suggesting continued regulation 337 
of the HPA axis during this entire period. 338 
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dehydrogenase type 2; CHA: congenital adrenal hyperplasia; CYP11A1: cytochrome P450 11A1; CYP11B1/2: 420 
cytochrome P450 11B; CYP17A1: cytochrome P450 17A1; CYP21A2: cytochrome P450 21A2; DHEAS: 421 
dehydroepiandrosterone sulfate; DZ: definitive zone; FZ: fetal zone; GW gestational week; HFA: human fetal 422 
adrenal; HPA: hypothalamus-pituitary-adrenal; IHC: immunohistochemistry; MC2R: melanocortin receptor; 423 




Figure 1. Gene Expression Level of Human Fetal Adrenal Steroidogenic Enzymes during 1st 426 
and 2nd Trimester 427 
(a-i) qRT-PCR analysis of a range of steroidogenic associated enzymes and receptors in male and 428 
female human fetal adrenal samples divided into four age groups: GW 8-9, GW 10-12, GW 14-16, 429 
and GW 17-19. Expression is relative to the reference gene RSP20. Expression level is set to 1 in 430 
male GW 8-9 samples.  In total 39 adrenal samples were used. Bars represent mean +/- SEM with 431 
individual data points shown as blue triangles and red circles, male and female samples 432 
respectively, n=3-6. Differences in age compared with male GW8-9 indicated as significantly 433 
different * (P<0.05), **(P<0.01). (j) Overall human fetal adrenal transcript levels from 1st and 2nd 434 
trimester samples, n=39. Data points represent –ΔCt values (relative to housekeeping gene 435 
RSP20) of investigated gene transcript levels in individual adrenal samples (male and female). 436 
Error bars represent mean ± SD.  437 
 438 
Figure 2. Human Fetal Adrenal Gland Morphology and Zonation  439 
Schematic illustration of the morphological distinct zonation in (a) 1st trimester human fetal adrenals 440 
(GW 7-12) and (b) 2nd trimester human fetal adrenals (GW 14-19) viewed as a cross section of the 441 
gland. (c) HE and Mayer stainings of a 1st trimester human fetal adrenal gland. (d) HE and Mayer 442 
stainings of a 2nd trimester human fetal adrenal gland, scale bar corresponds to 100 µm. DZ:  443 
definitive zone TZ: transitional zone, FZ: fetal zone. 444 
 445 
Figure 3. Expression of Steroidogenic Enzymes in 1st and 2nd Trimester Human Male Adrenal 446 
Glands 447 
Immunohistochemical staining of serial sections for: CYP11A1, CTP17A1, 3β-HSD1/2, CYP21A2, 448 
CYP11B1 and SULT2A1 (steroidogenic proteins) as well as MC2R (ACTH receptor) in male 449 
samples. No differences were observed between male and female samples within a given 450 
gestational group and therefore only male samples are shown. Scale bars = 100 µm. 451 
 452 
Figure 4. Tissue Levels of Steroid in 1st and 2nd Trimester Human Adrenals 453 
 
  
LC-MS/MS measurements (ng/g wet tissue) of secreted adrenal steroid hormones determined from 454 
male and female adrenal tissue extracts. Bars represent mean +/- SEM with individual data points 455 
shown as blue triangles and red circles, male and female samples respectively, n=3-5. Differences 456 
in age compared with male GW8-9 indicated as significantly different * (P<0.05). Differences 457 
between sex within the same age group are indicated as significantly different ¤ (P<0.05). 458 
 459 
Figure 5. Overview of Human Fetal Adrenal Steroidogenic Development  460 
(a) Schematic overview of adrenal steroidogenesis. Gene transcripts of enzymes significantly 461 
upregulated in 2nd trimester is shown in green boxes, with unaltered gene transcripts shown in red 462 
boxes. Measured steroid hormones are shown in the bold text font. (b) Overview of steroid hormone 463 
levels relative to progesterone levels throughout the investigated developmental period. Data are 464 




Table 1. Primers used for RT-PCR and Quantitative PCR  467 
Gene HGNC ID Forward Primer Reverse Primer Application 
size 
StAR 11359 CACCCCTAGCACGTGGATTA  CTTGGTTGCTAAGGATGCCC 152 bp 
CYP11A1 2590 ATAAACCGACTCCACGTTGC ACAATGGCTGGCTAAACCTG 134 bp 
CYP17A1 2593 GAGTTTGCTGTGGACAAGGG CGCTGGATTCAAGAAACGCT 117 bp 
3β-HSD2 5218 CAGGCTCTTTTCAGGAATGG CTTGGACAAGGCCTTCAGAC 117 bp 
CYP21A2 2600 GAGTTCTGTGAGCGCATGAG GAATCACGTCCACAATTTGGAT  205 bp 
CYP11B1/2 2591/2 CTTCCACTACACCATAGAAGCCAGC CCTCAAAGTGCTCCTTCCACAC 200 bp 
ARK1C3 386 GGAGGCCATGGAGAAGTGTAAGGA CCAGAGCACTATAGGCAACCAGAAC 215 bp 
SULT2A1 11458 ACAGGACACAGGAAGAACCATAGAG CTTCAGCTTGGGCCACTGTGAA 230 bp 
MC2R 6930 ACATGGGCTATCTCAAGCCAC TCCAGATGACCGTAAGCACCA 204 bp 
RSP20 10405 AACAAGCCGCAACGTAAAATC ACGATCCCACGTCTTAGAACC 166 bp 
SRY 11311 GAATATTCCCGCTCTCCGGA GCTGGTGCTCCATTCTTGAG 470 bp 
 468 




Table 2. Antibodies, Dilutions and Retrieval Buffers used 471 
Antibody Dilution Retrieval 
buffer 
Species Supplier Number 
CYP11A1 1:10.000 TEG Rabbit Sigma HPA016436 
CYP17A1 1:1500 CIT Rabbit Abcam Ab134910 
3β-HSD1/2 1:6000 TEG Rabbit  Gift from Ian 
Mason 
-  
CYP21A2 1:6000 TEG Goat Santa Cruz 
Biotechnology 
Sc-48466 
CYP11B1 1:3000 TEG Mouse Santa Cruz 
Biotechnology 
Sc-374096 
SULT2A1 1:6000 CIT Rabbit Sigma HPA041487 
MC2R 1:800 TEG 
 




Antigen retrieval was conducted by pressure cooking of the sections in indicated retrieval buffer for 473 
30 min. in a decloaking chamber. TEG buffer: 10 mM Tris, 0.5 mM EGTA, pH 9.0; Citrate (CIT) 474 
buffer: 10 mM, pH 6.0. 475 
 
  
Table 3. Analysis of Adrenal Zone-Specific Protein Localization and Level of Expression 476 
 DZ FZ C 




8-9 10-12 14-16 17-19 8-9 10-12 14-16 17-19 17-19 
CYP11A1 +(2) +(2) +(2) +/++/- ++ ++/+ ++/+ ++/+  
CYP17A1 -/+ +(2) +(2) +(2) ++/+ ++/+ ++ (TZ), ++/+(FZ) ++(TZ), ++/+(FZ)  
SULT2A1 +(2) +(2) +(2) +(2) ++/+ ++/+ ++/+ ++/+  
MC2R +(1) +/++ +/++, +/++/-(n) +(1), ++/-(n) +/++ +/++ +/++, -/+(n) +/++, +/++/-(n) ++/-(n) 
CYP11B1 +/- -/+  -/+ -/+ +/- +/- +(1) +(1)  
CYP21A2 -/+ +(2) +(2) +(2) +/++ ++/+ ++/+ ++/+  
3βHSD1/2 ++/- ++/- +/++/- +/++/- +(2) +(2) +(2) +(2)  
 477 
GW: gestational week, DZ: Distal Zone, FZ: Fetal Zone, TZ: transitional zone, C: Capsule, n: nuclear staining.  478 
n = 6-15 adrenals within each gestational group. 479 
TZ staining is indicated when the TZ protein expression differed from the FZ expression in the 2nd trimester tissue (GW: 14-19).    480 
Scale: ++, strong staining in all cells of a given type in the sample; ++/+, strong staining prevalent, but some weakly stained cells also visible;  481 
++/-, strong staining present, but negative cells also present; +/++, majority of cells weakly stained, but some strong staining present; +/++/-482 
, heterogeneous pattern with a mixture of strongly positive, weakly stained, and negative cells; +, (1) weak staining overall or (2) strong 483 
staining in a small number of cells; +/-, weak staining in limited areas; -/+, weak staining in single cells. 484 
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